605
26.4.6 Recombinant DNA Technology in Disease Diagnosis
Recombinant DNA procedure is now greatly used to identify and treat human
pathology by detecting a molecular defect in humans. It also helps to understand
and detect genetic diseases, which were previously considered as non-treatable diseases. Other diseases like infectious diseases and neoplasia or due to mutation or
deletion of nucleotides at one or more sites can also be diagnosed, which will be
helpful in medicine. In the twentieth-century, recombinant DNA technology is a
rapidly growing field, especially in disease diagnosis. Due to development of these
techniques, the physician is able to diagnose the disease with more accuracy.
Scientists working in DNA technology are struggling for improvement of procedures so that it is accessible, affordable and acceptable to the community.
26.4.7 Recombinant DNA Pharmaceuticals
Recently, molecular medicine formulation synthesized by using different molecular
genetics methods are helpful for the investigation of disease, defective genes identification and for replacement of abnormal gene functioning with normal ones. The
study of disease-causing genes responsible for disease and its expression in the
normal individual has been possible by the advancement of recombinant DNA and
by adopting advanced cloning techniques. The term gene cloning is commonly used
for different methods suitable and most effective to utilize DNA in a test tube and
also to return it within an expression system where it acts efficiently. The tools that
are commonly used for the purpose of gene cloning include suitable vectors, genes
incorporation, and the enzymes synthesis. The biological, and methodological
obstacle created by cell factories for the production or rDNA pharmaceuticals is the
main challenge in the development of protein-based molecular medicine.
Recombinant DNA technologies might have an ability to exhaust conventional cell
factories, thus new production systems need to be deeply explored and incorporated
into the production pipeline. More thoughtful comprehension to overcome problems of host cell physiology and cell responses during protein production and biological stress would necessarily require more suitable tools and techniques (either at
genetic, metabolic or system levels) to boost high-yield and production of high–
valuable proteins. Apart from the expected integration of unusual mammalian hosts
such as transgenic animals or plants, microbial cells prove as exceptionally strong
and suitable hosts, and gaining knowledge about the biological aspects of protein
production would hopefully boost the performance of such hosts. In view of this,
not only commonly used bacterial and yeasts cell but unconventional strains or species are under observation as promising cell factories for synthesizing recombinant
drugs. Their incorporation into productive processes for human pharmaceuticals
would hopefully push the trend of marketed products and prove to be helpful for
overcoming the demands of pharmacological companies.
26 Genetic Engineering of Novel Products of Health Significance: Recombinant DNA…
26.4.6 Recombinant DNA Technology in Disease Diagnosis
Recombinant DNA procedure is now greatly used to identify and treat human
pathology by detecting a molecular defect in humans. It also helps to understand
and detect genetic diseases, which were previously considered as non-treatable diseases. Other diseases like infectious diseases and neoplasia or due to mutation or
deletion of nucleotides at one or more sites can also be diagnosed, which will be
helpful in medicine. In the twentieth-century, recombinant DNA technology is a
rapidly growing field, especially in disease diagnosis. Due to development of these
techniques, the physician is able to diagnose the disease with more accuracy.
Scientists working in DNA technology are struggling for improvement of procedures so that it is accessible, affordable and acceptable to the community.
26.4.7 Recombinant DNA Pharmaceuticals
Recently, molecular medicine formulation synthesized by using different molecular
genetics methods are helpful for the investigation of disease, defective genes identification and for replacement of abnormal gene functioning with normal ones. The
study of disease-causing genes responsible for disease and its expression in the
normal individual has been possible by the advancement of recombinant DNA and
by adopting advanced cloning techniques. The term gene cloning is commonly used
for different methods suitable and most effective to utilize DNA in a test tube and
also to return it within an expression system where it acts efficiently. The tools that
are commonly used for the purpose of gene cloning include suitable vectors, genes
incorporation, and the enzymes synthesis. The biological, and methodological
obstacle created by cell factories for the production or rDNA pharmaceuticals is the
main challenge in the development of protein-based molecular medicine.
Recombinant DNA technologies might have an ability to exhaust conventional cell
factories, thus new production systems need to be deeply explored and incorporated
into the production pipeline. More thoughtful comprehension to overcome problems of host cell physiology and cell responses during protein production and biological stress would necessarily require more suitable tools and techniques (either at
genetic, metabolic or system levels) to boost high-yield and production of high–
valuable proteins. Apart from the expected integration of unusual mammalian hosts
such as transgenic animals or plants, microbial cells prove as exceptionally strong
and suitable hosts, and gaining knowledge about the biological aspects of protein
production would hopefully boost the performance of such hosts. In view of this,
not only commonly used bacterial and yeasts cell but unconventional strains or species are under observation as promising cell factories for synthesizing recombinant
drugs. Their incorporation into productive processes for human pharmaceuticals
would hopefully push the trend of marketed products and prove to be helpful for
overcoming the demands of pharmacological companies.
26 Genetic Engineering of Novel Products of Health Significance: Recombinant DNA…